- BioLife Solutions ( NASDAQ: BLFS ) reported preliminary and unaudited Q4 revenue of $44.M, an increase of 19% Y/Y, vs consensus of $43.42M . COVID related revenue accounted for ~5% of total revenue.
- Q4 Cell processing platform revenue was $20.3M, up $5.5M, or 37% Y/Y. All growth was organic.
- Q4 Freezers and Thaw Systems platform revenue was $17.4M, up $0.8M, or 5%Y/Y. COVID related revenue accounted for ~3% of the freezers and thaw systems platform revenue. All growth was organic.
- Q4 Storage and Storage Services platform revenue was $6.7M, up $0.8M, or 15%Y/Y.
- FY22 preliminary and unaudited revenue for the full year 2022 was $161.9M, an increase of 36% Y/Y vs consensus of $160.92M , with organic revenue growth of 38%. COVID related revenue accounted for ~8% of total revenue.
- FY Cell processing platform revenue was $68.6M, up $23.7M, or 53% Y/Y. Organic growth was 45%.
- FY Freezers and Thaw Systems platform revenue was $66.8M, up $10.1M, or 18% Y/Y. COVID related revenue accounted for ~4% of the freezers and thaw systems platform revenue. Organic growth was 9%.
- FY Storage and Storage Services platform revenue was $26.5M, up $9.0M, or 51% Y/Y. COVID related revenue accounted for ~39% of the storage and storage services platform revenue. Organic growth was 51%.
- The company expects full year positive Adjusted EBITDA for FY22.
- For FY23 the company expects total revenue in the range $188M to $202M, reflecting Y/Y growth of 16% to 25%, vs consensus of $195.45M and full year positive Adjusted EBITDA and Adjusted EBITDA growth in 2023.
- Shares are trading down 1.24% premarket.
For further details see:
BioLife Solutions guides Q4 and FY22 revenue above consensus, initiates FY23 guidance